NRX Pharmaceuticals (NRXP) said Monday that it has completed 12 months of demonstrating the stability of its first manufactured lot of NRX-100, or Ketamine, at Nephron Pharmaceuticals.
NRX Pharmaceuticals said reaching the stability milestone will help support its submission of a new drug application with the US Food and Drug Administration to use intravenous ketamine to treat suicidal depression.
The biopharmaceutical company also said the NDA filing for NRX-100 "is on track for 2024."
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。